EMERGING TESTS

Study Showing PGx Testing Improves Depression Outcomes, Key to Myriad’s Reimbursement Strategy

Pharmacogenomic testing (PGx) provides clinically meaningful improvement in response and remission rates for difficult-to-treat depression patients over standard of care, according to a study … [Read more...]

INDUSTRY TRENDS

Diagnostics Sector Saw Increased Investment, Exits in 2018

Life science and health care companies had a banner year in 2018, with a record-breaking year for venture capital investment, according to Silicon Valley Bank's Trends in Healthcare Investments and … [Read more...]

EMERGING TESTS

Sequencing Shows Promise in Care of Common Kidney Disease

Exome sequencing can yield a genetic diagnosis in almost 10 percent of patients with chronic kidney disease (CKD), according to a study published Jan. 10 in the New England Journal of Medicine. This … [Read more...]

PRECISION MEDICINE

Newborn Sequencing Delivers Some Unanticipated Findings

Newborn genomic sequencing (NGS) can identify risk for a wide range of disorders that otherwise may not be detected, even in seemingly healthy babies, according to a study published Jan. 3 in the … [Read more...]

THE BUSINESS OF TESTING

Payer Medical Policies Can Promote Effective Use of Comprehensive Sequencing In Community Oncology Setting

Comprehensive genomic profiling (CGP) identifies clinically relevant genomic alterations that can be used to inform treatment decisions in community-based oncology practices that benefit both patients … [Read more...]

GENETIC TESTING

Most Oncologists Report Using Sequencing-Based Panels In Practice

The majority of U.S. oncologists report using next-generation sequencing-based (NGS-based) tests to guide patient care, according to a study published Nov. 13 in JCO Precision Oncology, although use … [Read more...]

SPECIAL FOCUS

Evidence Building for Use of Liquid Biopsy to Drive Treatment Decisions, Monitor Disease Activity

Emerging evidence shows that liquid biopsy is a viable option for detecting and monitoring genomic mutations to inform treatment decisions and to assess disease activity in real-world clinical … [Read more...]

EMERGING TESTS

Polygenic Risk Score Predicts Drug Efficacy with Schizophrenia

A polygenic risk score (PRS) may be able to predict response to antipsychotic drug treatment in patients with their first episode of psychosis from schizophrenia, according to a study published Nov. 5 … [Read more...]

PRECISION MEDICINE

Panel Size Affects Accuracy of Tumor Mutational Burden Calculation

Panel size is a critical determinant of test performance and cutoff values for determining the tumor mutational burden (TMB) to guide treatment decisions with immunotherapies, according to a study … [Read more...]

GENETIC TESTING

Sequencing-Based Panel May Improve Evaluation of Thyroid Nodules

A genetic test panel can help patients avoid unnecessary diagnostic thyroid surgeries, according to a study published Nov. 8 in JAMA Oncology. More than six in 10 of patients with thyroid nodules of … [Read more...]


(-00000g2)